Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study

Executive Summary

Private payers may have difficulty realizing a positive short term return on investment for covering a targeted breast cancer therapy like Genentech's Herceptin - at least based on individual patient costs, a study by the Deloitte Center for Health Solutions finds
Advertisement

Related Content

With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine
Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine
Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine

Topics

Advertisement
UsernamePublicRestriction

Register

PS050731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel